What it is
Plecanatide is a peptide of 16 amino acids that copies uroguanylin, a hormone the small intestine makes for itself. It is sold in the United States as Trulance, a 3 mg tablet, first approved on 19 January 2017 for chronic idiopathic constipation (Drugs@FDA, NDA 208745, sponsor Salix). The current label adds irritable bowel syndrome with constipation, both in adults.
The label gives the chain as NDECELCVNVACTGCL, folded by two sulfur-to-sulfur bridges between cysteines 4 and 12 and between 7 and 15 (Trulance label, section 11).
| Property | Value | Source |
|---|---|---|
| Length | 16 amino acids | Trulance label |
| Sequence | NDECELCVNVACTGCL | Trulance label |
| Disulfide bridges | Cys4–Cys12, Cys7–Cys15 | Trulance label |
| Formula | C65H104N18O26S4 | Trulance label |
| Molecular weight | 1,682 Da | Trulance label |
| Natural template | Uroguanylin, 16 residues, cut from a 112-residue precursor | UniProt Q16661 |
One letter apart. UniProt's record for the human uroguanylin precursor (Q16661, read 2026-11-16) gives the mature hormone as NDDCELCVNVACTGCL. Set beside the label sequence, the two differ only at position 3 — aspartic acid (D) in the hormone, glutamic acid (E) in the drug (our comparison). The four sulfur atoms in the drug's formula match its four cysteines.
How it works
Plecanatide binds guanylate cyclase-C, a receptor on the cells lining the intestine. For the same receptor, the Linzess label describes the chain of events: a rise in cyclic GMP inside the cell opens the CFTR channel, chloride and bicarbonate pass into the gut, and water follows. The drug acts on the inside surface of the gut: in a single-dose study in 72 healthy volunteers given between 0.1 and 48.6 mg, the authors described it as acting locally in the gastrointestinal tract (Shailubhai et al. 2013, PMID 23625291).
The same receptor is the target of linaclotide, the other approved peptide in this class, 14 amino acids long with three disulfide bridges.
What the trials showed
| Trial | People | Primary result over 12 weeks | Source |
|---|---|---|---|
| Chronic idiopathic constipation, phase 3 | 1,394 | Durable responders 21.0% (3 mg), 19.5% (6 mg), 10.2% placebo | Miner 2017, PMID 28169285 |
| IBS-C, study 1 | part of 2,189 | Overall responders 30.2% (3 mg), 29.5% (6 mg), 17.8% placebo | Brenner 2018, PMID 29545635 |
| IBS-C, study 2 | part of 2,189 | 21.5% (3 mg), 24.0% (6 mg), 14.2% placebo | Brenner 2018, PMID 29545635 |
In the constipation trial, complete spontaneous bowel movements rose by 2.5 a week on 3 mg against 1.2 on placebo. Diarrhoea was the most common adverse event: 5.9% on 3 mg, 5.7% on 6 mg, 1.3% on placebo.
What the numbers mean in plain terms: most people in every arm, drug or placebo, did not meet the responder definition. The drug roughly doubled the share who did. The trials ran 12 weeks; the 6 mg dose did no better than 3 mg, and the label lists only a 3 mg tablet.
Safety on the label
The Trulance label carries a boxed warning on serious dehydration in children. It is contraindicated under 6 years of age because, in nonclinical studies in young juvenile mice, a single oral dose caused deaths from dehydration. The label says to avoid it from 6 to under 18 and that safety and effectiveness have not been established under 18.
Where it stands
Plecanatide is a prescription drug with two adult indications in the United States. It is not a research peptide or a supplement, and no evidence in the record supports any other use. Questions about constipation treatment belong to a doctor; GLP1Ledger's constipation page covers the separate question of constipation on GLP-1 medicines.
Sources opened 2026-11-16: Trulance prescribing information (openFDA, revision 2024-04-04); Drugs@FDA NDA 208745; UniProt Q16661; Miner et al. 2017 (PMID 28169285); Brenner et al. 2018 (PMID 29545635); Shailubhai et al. 2013 (PMID 23625291); PubMed and ClinicalTrials.gov API v2 counts.
